skip to Main Content

AI-Based CompCyst Test Shows Promise in Pancreatic Cancer Study SHARE

Newsfeed image, light gray text on dark gray background
A proof-of-concept study led by Johns Hopkins Kimmel Cancer Center in the US has found CompCyst, an artificial intelligence (AI)-based laboratory test, could accurately identify pancreatic cysts that will develop into cancers.

CompCyst builds on patient data including clinical impressions and symptoms, CT images, and molecular markers such as DNA alterations in cyst fluid. Read more . . . 

Back To Top